Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rixubis Continuation Study in Hemophilia B
NCT01286779Phase 3Completed
- Sponsor
- Takeda
- Start
- Apr 2011
- Primary completion
- Jun 2017
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 17
01
Overview
Phase 3, open-label, single-arm trial of trenonacog alfa in hemophilia B (HB), sponsored by Takeda. Primary endpoint: Adverse Events Possibly or Probably Related to the Investigational Product. Started Apr 2011; status: completed.
02
Drugs
trenonacog alfa
03
Conditions
hemophilia B (HB)
Beyond the preview
Go deeper on NCT01286779.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01286779.